Skip to content

Study · Animal study (in vivo) · mouse · 2023

5 results

Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.

Wang XX, Myakala K, Libby AE, Krawczyk E, Panov J, Jones BA, Bhasin K, Shults N, Qi Y, Krausz KW, Zerfas PM, Takahashi S and 15 more

Show all authors

Daneshpajouhnejad P, Titievsky A, Taranenko E, Billon C, Chatterjee A, Elgendy B, Walker JK, Albanese C, Kopp JB, Rosenberg AZ, Gonzalez FJ, Guha U, Brodsky L, Burris TP, Levi M

The American journal of pathology17 Sept 2023Cited by 34 (Europe PMC)

PMID37717940 (opens in a new tab)PMCIDPMC10734281 (opens in a new tab)DOI10.1016/j.ajpath.2023.07.008 (opens in a new tab)PepBankPUB-37717940
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In aged mice, SLU‑PP‑332 reversed age-related increases in albuminuria.

    In plain wordsIn mice, SLU‑PP‑332 reversed the increase in urine albumin associated with aging.

    Peptide
    SLU-PP-332
    Outcome
    DecreaseAlbuminuria
    Study

    mousen: not reported in source

    21-month-old mice
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Remarkably, similar to CR, an 8-week treatment with a pan-ERR agonist reversed the age-related increases in albuminuria, podocyte loss, mitochondrial dysfunction, and inflammatory cytokines, via the cyclic GMP-AMP synthase-STING and STAT3 signaling pathways.
    1 context sentence
    Summary · context
    A pan-ERR agonist, SLU-PP-332, was used to treat 21-month-old mice for 8 weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In aged mice, SLU‑PP‑332 reversed age-related increases in podocyte loss.

    In plain wordsIn mice, SLU‑PP‑332 reversed the increase in podocyte loss associated with aging.

    Peptide
    SLU-PP-332
    Outcome
    DecreasePodocyte loss
    Study

    mousen: not reported in source

    21-month-old mice
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Remarkably, similar to CR, an 8-week treatment with a pan-ERR agonist reversed the age-related increases in albuminuria, podocyte loss, mitochondrial dysfunction, and inflammatory cytokines, via the cyclic GMP-AMP synthase-STING and STAT3 signaling pathways.
    1 context sentence
    Summary · context
    A pan-ERR agonist, SLU-PP-332, was used to treat 21-month-old mice for 8 weeks.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In aged mice, SLU‑PP‑332 reversed age-related increases in mitochondrial dysfunction.

    In plain wordsIn mice, SLU‑PP‑332 reversed the increase in mitochondrial dysfunction associated with aging.

    Peptide
    SLU-PP-332
    Outcome
    DecreaseMitochondrial dysfunction
    Study

    mousen: not reported in source

    21-month-old mice
    Outcome group
    Mitochondrial function · Kidney and urinary
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Remarkably, similar to CR, an 8-week treatment with a pan-ERR agonist reversed the age-related increases in albuminuria, podocyte loss, mitochondrial dysfunction, and inflammatory cytokines, via the cyclic GMP-AMP synthase-STING and STAT3 signaling pathways.
    1 context sentence
    Summary · context
    A pan-ERR agonist, SLU-PP-332, was used to treat 21-month-old mice for 8 weeks.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In aged mice, SLU‑PP‑332 reversed age-related increases in inflammatory cytokines.

    In plain wordsIn mice, SLU‑PP‑332 reversed the increase in inflammatory cytokines associated with aging.

    Peptide
    SLU-PP-332
    Outcome
    DecreaseInflammatory cytokines
    Study

    mousen: not reported in source

    21-month-old mice
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Remarkably, similar to CR, an 8-week treatment with a pan-ERR agonist reversed the age-related increases in albuminuria, podocyte loss, mitochondrial dysfunction, and inflammatory cytokines, via the cyclic GMP-AMP synthase-STING and STAT3 signaling pathways.
    1 context sentence
    Summary · context
    A pan-ERR agonist, SLU-PP-332, was used to treat 21-month-old mice for 8 weeks.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In aged mice, cGAS-STING and STAT3 signaling pathways mediated the reported reversal of age-related changes with SLU‑PP‑332.

    In plain wordsIn mice, cGAS-STING and STAT3 signaling pathways mediated the reported SLU‑PP‑332 effects on age-related kidney changes.

    Peptide
    SLU-PP-332
    Outcome
    Not applicablecGAS-STING and STAT3 signaling mediation
    Study

    mousen: not reported in source

    21-month-old mice
    Outcome group
    Receptor activity and mechanism · Kidney and urinary
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Remarkably, similar to CR, an 8-week treatment with a pan-ERR agonist reversed the age-related increases in albuminuria, podocyte loss, mitochondrial dysfunction, and inflammatory cytokines, via the cyclic GMP-AMP synthase-STING and STAT3 signaling pathways.
    1 context sentence
    Summary · context
    A pan-ERR agonist, SLU-PP-332, was used to treat 21-month-old mice for 8 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.